{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
{{facet.count}}
Status:
Investigational
Class:
PROTEIN
Status:
Investigational
Source:
INN:exidavnemab [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03516981: Phase 2 Interventional Active, not recruiting Advanced Non-Small Cell Lung Cancer
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04370704: Phase 1/Phase 2 Interventional Active, not recruiting Melanoma
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03789604: Phase 3 Interventional Active, not recruiting Non Small Cell Lung Cancer
(2018)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
INN:dalutrafusp alfa [INN]
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03758001: Phase 1 Interventional Completed Advanced Solid Tumor
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04592653: Phase 1/Phase 2 Interventional Active, not recruiting Advanced Solid Tumor
(2020)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT03849469: Phase 1 Interventional Completed Melanoma
(2019)
Source URL:
Class:
PROTEIN
Status:
Investigational
Source:
NCT04529096: Phase 2 Interventional Completed Chronic Low-back Pain
(2020)
Source URL:
Class:
PROTEIN
